Literature DB >> 8844786

Accumulation of porphyrins in plasma and tissues of dogs after delta-aminolevulinic acid administration: implications for photodynamic therapy.

N G Egger1, M Motamedi, M Pow-Sang, E Orihuela, K E Anderson.   

Abstract

Protoporphyrin accumulates in tissues after administration of delta-aminolevulinic acid, and can be used as a photosensitizer for photodynamic therapy. To determine the distribution of porphyrins in a large animal model after administration of this porphyrin precursor, delta-aminolevulinic acid was administered to anesthetized dogs (100 mg/kg body weight intravenously) and porphyrin concentrations were measured in tissues (liver, pancreas, prostate, bladder, muscle and skin), plasma and urine for 6-10 h. Porphyrins increased markedly (up to 50-fold) in plasma within 1 h, were still markedly increased at 8 h, and consisted mostly of coproporphyrin III and protoporphyrin. Tissue porphyrin concentrations increased more slowly, were highest in liver, pancreas and prostate 7-10 h after delta-aminolevulinic acid administration, and were predominantly protoporphyrin. Maximum porphyrin concentrations in liver were 3- and 4-fold higher than in pancreas and prostate, respectively. Urinary delta-aminolevulinic acid excretion increased and was greatest 2-4 h after dosing; urinary porphobilinogen and porphyrins increased more gradually and remained increased up to at least 8 h. Coproporphyrin III was the predominant porphyrin in urine at all times, but hepta-, hexa- and pentacarboxyl porphyrins increased proportionally after administration of delta-aminolevulinic acid. These results indicate that porphyrins accumulate in plasma as well as tissues and urine after administration of delta-aminolevulinic acid, and may contribute to tumor necrosis during photodynamic therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8844786     DOI: 10.1159/000139403

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  4 in total

Review 1.  Porphyrias at a glance: diagnosis and treatment.

Authors:  Maria Domenica Cappellini; Valentina Brancaleoni; Giovanna Graziadei; Dario Tavazzi; Elena Di Pierro
Journal:  Intern Emerg Med       Date:  2010-10       Impact factor: 3.397

2.  Pilot study of mitochondrial bioenergetics in subjects with acute porphyrias.

Authors:  Natalia Dixon; Ting Li; Brandon Marion; Denise Faust; Stephen Dozier; Anthony Molina; Sean Rudnick; Herbert L Bonkovsky
Journal:  Mol Genet Metab       Date:  2019-05-20       Impact factor: 4.797

3.  Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency.

Authors:  Norman G Egger; Douglas E Goeger; Deborah A Payne; Emil P Miskovsky; Steven A Weinman; Karl E Anderson
Journal:  Dig Dis Sci       Date:  2002-02       Impact factor: 3.199

4.  X-chromosomal inactivation directly influences the phenotypic manifestation of X-linked protoporphyria.

Authors:  V Brancaleoni; M Balwani; F Granata; G Graziadei; P Missineo; V Fiorentino; S Fustinoni; M D Cappellini; H Naik; R J Desnick; E Di Pierro
Journal:  Clin Genet       Date:  2015-02-17       Impact factor: 4.438

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.